NR 567 FINAL EXAM – ADVANCED PHARMACOLOGY FOR THE
AGACNP | 2 VERSIONS EACH 100 Questions with Answers &
Rationales | instant pdf download
This 2 versions exam covers the core content areas for the NR 567 Advanced
Pharmacology final, including:
Pharmacokinetics & Pharmacodynamics
Antimicrobial Therapy (antibacterials, antifungals, antivirals)
Cardiovascular Pharmacology (HF, HTN, ACS, anticoagulation, antiarrhythmics)
Endocrine Pharmacology (diabetes, thyroid, adrenal, bone)
Neurology & Psychiatry (seizures, Parkinson's, Alzheimer's, depression,
psychosis)
Hematology & Oncology (anticoagulation, chemotherapy, supportive care)
Pulmonary Pharmacology (asthma, COPD, PAH)
Gastrointestinal Pharmacology (PUD, IBD, liver disease, nutrition)
Renal, Fluids & Electrolytes
High-Risk Medications & Patient Safety
,SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS PRINCIPLES (Questions
1-15)
1. A 78-year-old patient with decreased renal function is prescribed a renally excreted
medication. What pharmacokinetic parameter is most likely to be altered?
A) Absorption
B) Distribution
C) Metabolism
D) Clearance
Answer: D – Clearance
Rationale: Decreased renal function directly reduces drug clearance for renally excreted
medications, leading to prolonged half-life and risk of drug accumulation. This requires
dosage adjustment based on CrCl or eGFR.
2. Which phase of drug metabolism is most commonly affected by genetic
polymorphisms, leading to variable drug responses?
A) Phase I (CYP450 oxidation)
,B) Phase II (conjugation)
C) Phase III (transport)
D) Phase IV (elimination)
Answer: A – Phase I (CYP450 oxidation)
Rationale: CYP450 enzymes, particularly CYP2D6, CYP2C19, and CYP2C9, exhibit
significant genetic polymorphism, resulting in poor, intermediate, extensive, or ultrarapid
metabolizer phenotypes.
3. An elderly patient with low serum albumin is prescribed a highly protein-bound
drug. What effect does hypoalbuminemia have on this medication?
A) Decreased free drug concentration and reduced efficacy
B) Increased free drug concentration and potential toxicity
C) No significant change in drug levels
D) Increased drug metabolism by the liver
Answer: B – Increased free drug concentration and potential toxicity
Rationale: With fewer albumin binding sites, more drug remains unbound (free) and
pharmacologically active, increasing the risk of adverse effects and toxicity.
, 4. Which of the following best describes a drug with a narrow therapeutic index?
A) The drug is effective at very low doses
B) Small changes in dose or blood concentration may lead to therapeutic failure or toxicity
C) The drug has multiple indications
D) The drug requires once-daily dosing
Answer: B – Small changes in dose or blood concentration may lead to therapeutic
failure or toxicity
Rationale: Narrow therapeutic index drugs (e.g., warfarin, digoxin, aminoglycosides,
phenytoin) require careful monitoring because the difference between effective and toxic
doses is small.
5. A patient with cirrhosis is prescribed a prodrug that requires hepatic activation.
What effect is expected?
A) Increased drug efficacy
B) Decreased conversion to active metabolite and reduced therapeutic effect
C) No change in drug response
D) Increased risk of anaphylaxis
AGACNP | 2 VERSIONS EACH 100 Questions with Answers &
Rationales | instant pdf download
This 2 versions exam covers the core content areas for the NR 567 Advanced
Pharmacology final, including:
Pharmacokinetics & Pharmacodynamics
Antimicrobial Therapy (antibacterials, antifungals, antivirals)
Cardiovascular Pharmacology (HF, HTN, ACS, anticoagulation, antiarrhythmics)
Endocrine Pharmacology (diabetes, thyroid, adrenal, bone)
Neurology & Psychiatry (seizures, Parkinson's, Alzheimer's, depression,
psychosis)
Hematology & Oncology (anticoagulation, chemotherapy, supportive care)
Pulmonary Pharmacology (asthma, COPD, PAH)
Gastrointestinal Pharmacology (PUD, IBD, liver disease, nutrition)
Renal, Fluids & Electrolytes
High-Risk Medications & Patient Safety
,SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS PRINCIPLES (Questions
1-15)
1. A 78-year-old patient with decreased renal function is prescribed a renally excreted
medication. What pharmacokinetic parameter is most likely to be altered?
A) Absorption
B) Distribution
C) Metabolism
D) Clearance
Answer: D – Clearance
Rationale: Decreased renal function directly reduces drug clearance for renally excreted
medications, leading to prolonged half-life and risk of drug accumulation. This requires
dosage adjustment based on CrCl or eGFR.
2. Which phase of drug metabolism is most commonly affected by genetic
polymorphisms, leading to variable drug responses?
A) Phase I (CYP450 oxidation)
,B) Phase II (conjugation)
C) Phase III (transport)
D) Phase IV (elimination)
Answer: A – Phase I (CYP450 oxidation)
Rationale: CYP450 enzymes, particularly CYP2D6, CYP2C19, and CYP2C9, exhibit
significant genetic polymorphism, resulting in poor, intermediate, extensive, or ultrarapid
metabolizer phenotypes.
3. An elderly patient with low serum albumin is prescribed a highly protein-bound
drug. What effect does hypoalbuminemia have on this medication?
A) Decreased free drug concentration and reduced efficacy
B) Increased free drug concentration and potential toxicity
C) No significant change in drug levels
D) Increased drug metabolism by the liver
Answer: B – Increased free drug concentration and potential toxicity
Rationale: With fewer albumin binding sites, more drug remains unbound (free) and
pharmacologically active, increasing the risk of adverse effects and toxicity.
, 4. Which of the following best describes a drug with a narrow therapeutic index?
A) The drug is effective at very low doses
B) Small changes in dose or blood concentration may lead to therapeutic failure or toxicity
C) The drug has multiple indications
D) The drug requires once-daily dosing
Answer: B – Small changes in dose or blood concentration may lead to therapeutic
failure or toxicity
Rationale: Narrow therapeutic index drugs (e.g., warfarin, digoxin, aminoglycosides,
phenytoin) require careful monitoring because the difference between effective and toxic
doses is small.
5. A patient with cirrhosis is prescribed a prodrug that requires hepatic activation.
What effect is expected?
A) Increased drug efficacy
B) Decreased conversion to active metabolite and reduced therapeutic effect
C) No change in drug response
D) Increased risk of anaphylaxis
